– [ad_1]
PAINTING OF THE BOARD AND BENCH IN BLUEFIELD. >> WE WANT TO CONTINUE TO HELP YOU GET THE FAT ON THE BACK. WE HAVE ASKED QUESTIONS ABOUT THE COVID-19 VACCINE TO DOCTORS IN THE PITTSBURGH AREA. I TALKED TO DOCTOR AMESH ADALJA, LOCAL INFECTIOUS DISEASE EXPERT, TO GET SOME OF THESE ANSWERS. THIS THOMPSON HAS WRITTEN, IF ANYONE IS POSITIVE, HOW LONG BEFORE GET THE VACCINE? >> WHEN YOU TEST POSITIVE THE REASON WE TELL PEOPLE TO DELAY IN THE START IS BECAUSE WE DON’T HAVE A LOT OF VACCINE AND RENEW PEOPLE WHO HAD NATURAL IMMUNITY WERE PROTECTED. NOW VACCINES ARE MORE ABUNDANT. I TELL PEOPLE, WAIT UNTIL YOU ARE NOT CONTAGIOUS SO 10 DAYS AFTER THE SYMPTOMS HAVE BEGUN, JUST BECAUSE WE DON’T WANT TO EXPOSE VACCINATORS. THE 90-DAY PERIOD PEOPLE ARE TALKING ABOUT WAS SO THAT WE WOULD HAVE ENOUGH VACCINE, SO WE LEAVE PEOPLE IN FRONT OF YOU IF YOU ALREADY HAVE THE VIRUS. >> THIS IS IMPORTANT. MARIANNE HAS WRITTEN, WILL WE NEED TO BOOSTER SHOES IN THE FALL? DR. ADALJA: IT’S NOT CLEAR. WHAT WE NEED TO DO IS FOLLOW UP ON PEOPLE WHO HAVE BEEN VACCINATED OVER TIME, LOOK AT THEIR ANTIBODY LEVELS, SEE IF THEY REINFECT AND CLINICALLY IMPORTANT, THEN MAKE DECISIONS ABOUT THE RECALL. WE WILL LIKELY NEED SOME TYPE OF IMMUNITY INCREASE, I DON’T KNOW WHAT THE INTERVAL IS, IT IS IMPOSSIBLE TO KNOW IF IT WILL BE ANNUAL OR TWO YEARS, IT DEPENDS ON WHAT THE STUDIES SHOW. IT IS TOO TT TO KNOW WHAT THE PLAN WILL BE, IF ANY. IT’S IMPORTANT TO STUDY AND PREPARE FOR IT, BUT NOT SOMETHING WE HAVE ENOUGH DATA TO SAY DEFINITELY. I WOULD NOT BE SURPRISED IF IN THE FALL THERE WERE BOOSTERS. >> WE WANT TO ASK YOUR QUESTIONS TO OUR LOCAL MEDICAL EXPERTS. SHARE EVERYTHING YOU THINK WITH US. YOU CAN DO IT VIA THE WTAE FACEBOOK P
Pitt joins mixed trial of COVID-19 booster injections
The trial aims to investigate the safety and immune response of a mixed booster diet
Updated: 12:11 PM EDT June 28, 2021
Adults who are fully vaccinated will receive a “booster” dose of a COVID-19 vaccine in a clinical trial that aims to study the safety and immune response of a mixed booster regimen, the faculty said. of Medicine from the University of Pittsburgh. “As more and more variants of COVID-19 are identified, we need to understand how we as a community can stay protected,” said a statement from Dr Judy Martin, professor of pediatrics and member of the Pitt’s Center for Vaccine Research. “The design of the study is not to show whether we need booster vaccines. Its goal is to identify which vaccine combinations are safe and offer the greatest protection against the virus that causes COVID-19 and its variants. ”Pitt said that a study group will consist of adults fully vaccinated with the Johnson & Johnson, Moderna or Pfizer vaccine. Volunteers will receive a booster dose of another COVID-19 vaccine within 12 to 20 weeks of their initial vaccination schedule. The other group will consist of about 250 unvaccinated adults. Volunteers will receive the Moderna vaccine in two doses, followed by a booster dose of a vaccine approximately 12 to 20 weeks later. “Throughout the year, volunteer participants will provide blood samples, which will be used to study their immune response against new variants of COVID-19,” Pitt said. “If participants contract COVID-19 during Throughout the study, investigators will assess whether a variant of COVID-19 caused the infection. ”Pitt is one of 12 sites to participate in the National Institute of Allergy and Infectious Diseases trial Volunteers are now accepted for the study Click here for more information.
Adults who are fully vaccinated will receive a “booster” dose of a COVID-19 vaccine in a clinical trial that aims to study the safety and immune response of a mixed booster regimen, the faculty said. of Medicine from the University of Pittsburgh.
“As more and more variants of COVID-19 are identified, we need to determine how we, as a community, can remain protected,” said a statement from Dr. Judy Martin, professor of pediatrics and member of the Pitt’s Center for Vaccine Research. “The design of the study is not to show whether we need booster vaccines. Its goal is to identify which vaccine combinations are safe and provide the best protection against the virus that causes COVID-19 and its variants. . “
Pitt said a study group will consist of adults fully vaccinated with the Johnson & Johnson, Moderna or Pfizer vaccine. Volunteers will receive a booster dose of another COVID-19 vaccine within 12 to 20 weeks of their initial vaccination schedule.
The other group will consist of about 250 unvaccinated adults. Volunteers will receive the Moderna vaccine in two doses, followed by a booster dose of a vaccine approximately 12 to 20 weeks later.
“Throughout the year, volunteer participants will provide blood samples, which will be used to study their immune response against new variants of COVID-19,” Pitt said. “If participants contract COVID-19 for the duration of the study, investigators will assess whether a variant of COVID-19 caused the infection. “
Pitt is one of 12 sites to participate in the trial by the National Institute of Allergies and Infectious Diseases. Volunteers are now accepted for the study. Click here for more information.
.
[ad_2] [ad_1]
PAINTING OF THE BOARD AND BENCH IN BLUEFIELD. >> WE WANT TO CONTINUE TO HELP YOU GET THE FAT ON THE BACK. WE HAVE ASKED QUESTIONS ABOUT THE COVID-19 VACCINE TO DOCTORS IN THE PITTSBURGH AREA. I TALKED TO DOCTOR AMESH ADALJA, LOCAL INFECTIOUS DISEASE EXPERT, TO GET SOME OF THESE ANSWERS. THIS THOMPSON HAS WRITTEN, IF ANYONE IS POSITIVE, HOW LONG BEFORE GET THE VACCINE? >> WHEN YOU TEST POSITIVE THE REASON WE TELL PEOPLE TO DELAY IN THE START IS BECAUSE WE DON’T HAVE A LOT OF VACCINE AND RENEW PEOPLE WHO HAD NATURAL IMMUNITY WERE PROTECTED. NOW VACCINES ARE MORE ABUNDANT. I TELL PEOPLE, WAIT UNTIL YOU ARE NOT CONTAGIOUS SO 10 DAYS AFTER THE SYMPTOMS HAVE BEGUN, JUST BECAUSE WE DON’T WANT TO EXPOSE VACCINATORS. THE 90-DAY PERIOD PEOPLE ARE TALKING ABOUT WAS SO THAT WE WOULD HAVE ENOUGH VACCINE, SO WE LEAVE PEOPLE IN FRONT OF YOU IF YOU ALREADY HAVE THE VIRUS. >> THIS IS IMPORTANT. MARIANNE HAS WRITTEN, WILL WE NEED TO BOOSTER SHOES IN THE FALL? DR. ADALJA: IT’S NOT CLEAR. WHAT WE NEED TO DO IS FOLLOW UP ON PEOPLE WHO HAVE BEEN VACCINATED OVER TIME, LOOK AT THEIR ANTIBODY LEVELS, SEE IF THEY REINFECT AND CLINICALLY IMPORTANT, THEN MAKE DECISIONS ABOUT THE RECALL. WE WILL LIKELY NEED SOME TYPE OF IMMUNITY INCREASE, I DON’T KNOW WHAT THE INTERVAL IS, IT IS IMPOSSIBLE TO KNOW IF IT WILL BE ANNUAL OR TWO YEARS, IT DEPENDS ON WHAT THE STUDIES SHOW. IT IS TOO TT TO KNOW WHAT THE PLAN WILL BE, IF ANY. IT’S IMPORTANT TO STUDY AND PREPARE FOR IT, BUT NOT SOMETHING WE HAVE ENOUGH DATA TO SAY DEFINITELY. I WOULD NOT BE SURPRISED IF IN THE FALL THERE WERE BOOSTERS. >> WE WANT TO ASK YOUR QUESTIONS TO OUR LOCAL MEDICAL EXPERTS. SHARE EVERYTHING YOU THINK WITH US. YOU CAN DO IT VIA THE WTAE FACEBOOK P
Pitt joins mixed trial of COVID-19 booster injections
The trial aims to investigate the safety and immune response of a mixed booster diet
Updated: 12:11 PM EDT June 28, 2021
Adults who are fully vaccinated will receive a “booster” dose of a COVID-19 vaccine in a clinical trial that aims to study the safety and immune response of a mixed booster regimen, the faculty said. of Medicine from the University of Pittsburgh. “As more and more variants of COVID-19 are identified, we need to understand how we as a community can stay protected,” said a statement from Dr Judy Martin, professor of pediatrics and member of the Pitt’s Center for Vaccine Research. “The design of the study is not to show whether we need booster vaccines. Its goal is to identify which vaccine combinations are safe and offer the greatest protection against the virus that causes COVID-19 and its variants. ”Pitt said that a study group will consist of adults fully vaccinated with the Johnson & Johnson, Moderna or Pfizer vaccine. Volunteers will receive a booster dose of another COVID-19 vaccine within 12 to 20 weeks of their initial vaccination schedule. The other group will consist of about 250 unvaccinated adults. Volunteers will receive the Moderna vaccine in two doses, followed by a booster dose of a vaccine approximately 12 to 20 weeks later. “Throughout the year, volunteer participants will provide blood samples, which will be used to study their immune response against new variants of COVID-19,” Pitt said. “If participants contract COVID-19 during Throughout the study, investigators will assess whether a variant of COVID-19 caused the infection. ”Pitt is one of 12 sites to participate in the National Institute of Allergy and Infectious Diseases trial Volunteers are now accepted for the study Click here for more information.
Adults who are fully vaccinated will receive a “booster” dose of a COVID-19 vaccine in a clinical trial that aims to study the safety and immune response of a mixed booster regimen, the faculty said. of Medicine from the University of Pittsburgh.
“As more and more variants of COVID-19 are identified, we need to determine how we, as a community, can remain protected,” said a statement from Dr. Judy Martin, professor of pediatrics and member of the Pitt’s Center for Vaccine Research. “The design of the study is not to show whether we need booster vaccines. Its goal is to identify which vaccine combinations are safe and provide the best protection against the virus that causes COVID-19 and its variants. . “
Pitt said a study group will consist of adults fully vaccinated with the Johnson & Johnson, Moderna or Pfizer vaccine. Volunteers will receive a booster dose of another COVID-19 vaccine within 12 to 20 weeks of their initial vaccination schedule.
The other group will consist of about 250 unvaccinated adults. Volunteers will receive the Moderna vaccine in two doses, followed by a booster dose of a vaccine approximately 12 to 20 weeks later.
“Throughout the year, volunteer participants will provide blood samples, which will be used to study their immune response against new variants of COVID-19,” Pitt said. “If participants contract COVID-19 for the duration of the study, investigators will assess whether a variant of COVID-19 caused the infection. “
Pitt is one of 12 sites to participate in the trial by the National Institute of Allergies and Infectious Diseases. Volunteers are now accepted for the study. Click here for more information.
.
[ad_2]